Community

MTN Nigeria Plc has delivered a remarkable turnaround in Q1 2025, with profit after tax surging by 134% year-on-year to ₦133.64 billion , a significant recovery from the ₦392.7 billion loss reported in Q1 2024 , firmly signaling the telecom giant’s return to profitability. Key Financial Highlights: Revenue: ₦1.057 trillion ▲ +40.5% YoY (Q1 2024: ₦753 billion) Profit After Tax: ₦133.64 billion ▲ +134% YoY EBITDA: Up 65.9%; EBITDA Margin: 46.6% ▲ +7.2 ppts Free Cash Flow: ₦209.9 billion ▼ -54.8%, impacted by accelerated capex Net FX Losses: ₦5.5 billion ▼ -99.2% (Q1 2024: ₦656.4 billion) Net Finance Costs: ₦134.5 billion ▼ -44% YoY Capex: ₦202.4 billion ▲ +159% YoY Operational Drivers and Strategic Execution MTN’s strong topline performance was fueled by a 51.5% surge in data revenue (₦529.4 billion) and 27.7% increase in voice revenue (₦407.4 billion).

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.

Key Takeaways Capstone is building a scalable platform in specialty construction materials, focusing on thin veneer masonry in the U.S. Midwest and Northeast. With a strategy of tuck-in acquisitions, innovative proprietary products, and regional growth, revenue could triple by 2030.

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.

U.S. jewelry sales advanced a tepid 1.3% in 2024, driven primarily by price increases as the number of units sold dropped 1.6%, according to industry analyst Edahn Golan of Tenoris. Yet, while American consumers largely hit the pause button on new jewelry purchases, the accessible-luxury jewelry brand Pandora posted 8% same-store sales growth in the U.S. last year.

Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.

EBIT-margin trajectory: Historical: 2.3 % → 3.6 % (FY 22/23) ​, down to – 2 % (FY 23/24) ​, back to 3 % in Q1 24/25 ​ Forecast: Gradual recovery to 4–6 % by FY 25/26, reaching 6–8 % by FY 29/30 Revenue growth: Historical: + 70 % (FY 22/23) ​, + 30 % (FY 23/24) ​, + 27 % (Q1 24/25) ​ Forecast: ~ 15 % CAGR over the next five years (FY 24/25–29/30) Five-year share-price goal: Current fair value: € 8.5–9.0 per share Five-year target: € 14–15 per share (≈ 1.9 bn EUR market cap) Enterprise value (EV) outlook (DCF-based): Revenues rising to ~ 1.8 bn EUR by FY 29/30 EBIT of ~ 145 m EUR (8 % margin) → NOPAT ~ 102 m EUR FCF margin ~ 5 % → ~ 90 m EUR FCF Terminal-value multiple: EV/FCF = 15 → TV ~ 1.35 bn EUR Discounted EV: ≈ 1.18 bn EUR + net cash 0.69 bn EUR → ≈ 1.87 bn EUR → ~ 14.8 EUR/share Top risks: execution delays, margin pressure from competition, raw-material cost swings, subsidy uncertainty, heavy capex needs Narrative Outlook Over the next five years, thyssenkrupp nucera is poised to leverage its unique position at the intersection of mature Chlor-Alkali expertise and rapid Green-Hydrogen adoption. After a transitional phase in FY 23/24 with negative margins driven by upfront investments, the company’s shift toward series-manufactured AWE modules and high-growth project backlog supports a steady margin recovery.

Full disclosure. I am a shareholder at the time of writing this.

Over the coming decade, two forces converge to transform Vossloh’s prospects: Germany’s unprecedented €500 billion infrastructure fund and the strategic bolt-on of Sateba, Europe’s leading concrete-sleeper maker. Together they unlock fresh markets, deepen Vossloh’s moat, and set the stage for multi-year revenue and earnings growth.